contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


hca-biosnack-update-biotech-and-life-science-stocks-outperform-as-the-general-stock-market-moves-to-record-highs

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Equity Research Analyst

Henrik Ekman

Philip Coombes

CEO, Sweden

Claus Thestrup

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Ascelia Pharma er et svensk biotechselskab med fokus på lægemidler til cancer behandlinger. Selskabet udvikler og kommercialiserer lægemidler, der er målrettet mod medicinske behov som endnu ikke bliver opfyldt og har en klar udviklings- og markedsvej. Ascelia Pharma har to pipeline-produkter, nemlig Orviglance og Oncoral. Orviglance (tidligere Mangoral) er selskabets hovedprodukt. Orviglance er i et fase 3-studie og estimeres at blive godkendt i 2023. Orviglance er et nyt kontrastmiddel til MR-scanning, udviklet til at forbedre påvisning og visualisering af leverlæsioner (inklusiv lever metastaser – og primære tumorer) hos patienter med nedsat nyrefunktion. Derudover har selskabet et fase-2 studie produkt i Oncoral som estimeres at have en færdiggørelsesdato i 2024. Oncoral er en tablet som indtages dagligt med en etableret potent anti-tumor-effekt – selv i svært behandlende kræftformer med potentiale for at tilbyde bedre patientresultater. Oncoral øger patientsikkerheden i og med patienten får en mildere dosis dagligt i form af en tablet, fremfor løbende intravenøse højdosis infusioner på hospitalet. English:  Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments.  They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance (Former working name Mangoral) is their main product which is a phase 3 study with an estimated completion date in June 2022. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel.

It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets. 

Hej Andreas, Jeg kan godt forstår, at det kan være svært at holde hoved og hale på det hele. Det er ikke unormalt i en godkendelsesproces med myndighederne.  Det er en dynamisk proces og der er ingen endelig dato for hvornår FDA kommer med et endeligt svar.  Selskabet har dog bekræftet flere gange, at man har en god dialog med FDA.  Håber det giver en smule mere indsigt i hvad der sker.

Har I noget overblik over deres tidslinje for ansøgningen ved FDA - Efter ændringen og spørgsmål fra FDA, så kan jeg ikke længere finde hoved og hale i hvornår FDA bør komme med den afgørelse?

BioPorto præsenterede i går deres Q3 regnskab i samarbejde med HC Andersen Capital. Der blev snakket om alt fra nøgletallene fra det seneste kvartal til hvordan deres dataindsamling fungerede. Tænker I at deres gode kursudvikling vil fortsætte mod årsskiftet?

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  BioPorto er et dansk In-vitro diagnostisk (IVD) selskab med hovedkontor i København, Danmark. Selskabet blev grundlagt i 2000. BioPorto har allerede ét produkt på markedet, NGAL-testen, som er til tidlig diagnosticering af akutte nyreskade (AKI). Den er kommercielt tilgængelig i Europa, Canada, Asien og Israel. NGAL-testen har modtaget banebrydende betegnelser fra FDA for akutte nyreskader til babyer, børn og unge under 18 år for hvilken den i øjeblikket udfører dataanalyser efter afslutningen af indrulning af patienter til dets fase 3-studie, som vil føre til en ansøgning til FDA. Fremtidige planer inkluderer yderligere FDA-indsendelse til voksenindikation såvel som andre markeder. English:  BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel.  It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for an adult indication as well as other markets.

BioPorto

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.

Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Så er der en ny analyse af Curasight ude fra HC Andersen Capital  Hele analysen kan læses her: Curasight: (One-pager) Updated after positive pipeline indications Jeg har sammenfattet lidt kort derfra her:   Virksomhedsprofil: Curasight er en dansk biotekvirksomhed etableret i 2013 med hovedsæde i København. De udvikler teknologier baseret på uPAR-receptoren, der kun findes i kræftceller. Deres produkter, uTRACE og uTREAT, sigter mod at diagnosticere og behandle kræft.   Investeringscase: Curasights investeringscase afhænger af en succesfuld udvikling og kommercialisering af deres uTRACE og uTREAT teknologier gennem partnerskaber.   Risici: Der er risici ved udviklingen af nye teknologier og usikkerhed om godkendelse og kommercialisering. Der er også risiko for, at partnerskabsaftalerne ikke vil være kommercielt vellykkede. Markedsvilkår og behovet for yderligere finansiering kan desuden også påvirke virksomheden.   Investeringsskabende faktorer: Curasight har bevist konceptet for deres diagnostiske teknologi og oplever derved interesse fra både videnskabelige og farmaceutiske interesseranter. Der er potentiale for bred anvendelse af deres teknologi.   Finansiel position: Curasight har en likviditetsposition på DKK 32,1 millioner ved udgangen af Q2 2023 og forventer yderligere indtægter fra Curium-partnerskabet. Virksomheden planlægger at sælge deres produkter gennem partnere, hvilket reducerer kommerciel risiko.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Curasight er en dansk biotekvirksomhed med fokus på at udvikle og forbedre opdagelsen og behandlingen af kræft på en mere skånsom og effektiv måde. På nuværende tidspunkt modtager patienter radioaktiv stråling i behandlingen mod kræft. Dette skader kræftcellerne, såvel som raske celler og væv i kroppen. Curasight teknologi er baseret på formålet om ikke at skade raske celler og væv. Virksomheden har to pipeline-produkter, der begge bruger radionuklid (nuklearmedicin) til at forbedre diagnosticering og behandling af forskellige kræfttyper; uTRACE bruger den såkaldte uPAR receptore som sidder på kræftceller, som en biomarkør til at diagnosticere kræften, samt dens udvikling. Selskabets andet product uTREAT, anvender uPAR som en receptor til at behandle kræften. Baseret på stærke fase 2-data, der allerede er indsamlet i 2022, forventes Curasight at forberede fase 3 til uTRACE senere i 2022 og 2023 for følgende fire kræfttyper: prostata, hjerne, neuroendokrine og hoved- og halskræft. English:  Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as an attachment to treat cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Curasight

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

Biotekdirektør smager egen medicin: Deltager i klinisk forsøg med coronavaccine Adm. direktør Bent U. Frandsen fra biotekselskabet Expres2ion er blandt de 3000 frivillige, der har meldt sig til at deltage i vaccineselskabet Bavarian Nordics fase 3-forsøg med deres fælles udviklede covid-19 vaccine. Tidligere på ugen fik topchefen et vaccinestik. Jeg synes det er for cool!, men også meget tilfældigt med selve udvælgelsen. Du kan læse hele Bents egen kommentar her:                   linkedin.com              Bent Frandsen on LinkedIn: #covid19vaccine #clinicalstudy #phase3 | 16 comments    👍🏻 GETTING A TASTE OF MY OWN MEDICINE 👏🏻  This week I got a shot of COVID-19 vaccine in the ABNCoV2 Phase 3 clinical study in Denmark. How often do... 16 comments on LinkedIn

ExpreS2ion Biotechnologies offentliggjorde i morges deres tal for deres Q3 rapport, hvor de i den forbindelse afholdte en præsentation af netop denne for 2022. Jeg synes det var et spændende event, hvor de både nåede ind på deres resultater, mens de også tog et dybere kig på deres omkostninger. Dernæst nåede de ogå omkring deres Covid-19 vaccinekandidat og tog et kig på markedet som helhed. Afsluttende snakkede de desuden om nogle af de andre produktkandidater, som de har i deres pipeline

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  ExpreS2ion er en biotekvirksomhed med base i Danmark, men børsnoteret i Sverige. Virksomheden udvikler en portefølje af vacciner mod sygdomme som COVID-19, influenza og brystkræft gennem brugen af dets cellebaserede ekspressionssystem, ExpreS2, som er anerkendt for at håndtere protein udfordringer. ExpreS2ion har udviklet Expres2, som er en teknologiplatform til effektiv og hurtig ikke-klinisk udvikling og produktion af komplekse proteiner til nye vacciner og diagnostik. På nuværende tidspunkt er selskabets primære produkt corona-vaccinekandidaten, ABNCoV2 som er i fase 2, udviklet sammen med sin partner, AdaptVac, hvoraf ExpreS2ion ejer 34%. Vaccinekandidatens licensret tilhører Bavarian Nordic som har globale kommercialiseringsrettigheder og ansvar for yderligere klinisk udvikling af vaccinen. English:  ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34% of. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

FluoGuide is a Danish company active in medical technology. The company's business focus is found in research and development of treatments against various forms of cancer, with the greatest focus on the development of products that guide surgical interventions. The products bind to the cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

FluoGuide

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

NeoDynamics AB meddelte i går, at det indgår partnerskab med den globale distributions- og logistikgigant Uniphar Group for at sikre en succesfuld lancering af NeoNavia® i USA, dets innovative pulsbiopsisystem.  NeoDynamics couldn’t be more pleased to be partnering with Uniphar, a proven global partner to pharma and MedTech companies. Leveraging Uniphar’s customer service, logistics management and digital technology will allow us to aggressively hit the US market. The relationship with Uniphar is a key corporate development as we put all the pieces in place for the successful US launch of NeoNavia, fortæller Anna Eriksrud CEO af NeoDynamics.  Endnu et vigtig skridt for NeoDynamics i forbindelse med deres lancering af puls biopsi-systemet Neonavia på det amerikanske marked. Efter FDA godkendelsen i efteråret 2022 er der kommet fart på forberedelserne op til lanceringen. De har fået ledelse, partner til hjælp med lanceringen og nu også en distributionspartner på plads. Det totale marked for bryst biopsi vurderes til USD 830 mio. i 2025. Læs hele meddelelsen her.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  NeoDynamics AB (publ) er en svensk medicinsk teknologivirksomhed dedikeret til at fremme diagnosticering og behandling af brystkræft. Virksomhedens første produkt NeoNavia®, et nyt innovativt pulsbiopsisystem til ultralydsstyret vævsprøvetagning, er i øjeblikket ved at blive introduceret på markedet. Biopsisystemet er bygget på en patenteret pulsteknologi, baseret på forskning ved Karolinska Institutet i Sverige. NeoNavia er evalueret for brystkræftdiagnose på førende klinikker i Storbritannien, Tyskland og Sverige. Pulsbiopsisystemet er blevet brugt til vævsprøvetagning i bryst og aksillære lymfer hos over 500 patienter. English:  NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing the diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in the breast and axilla in over 500 patients.

NeoDynamics

Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.

Pharma Equity Group

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. The first capsules in the company's product, Egoo.Health Platform, were CE-marked for professional use in early 2020. The company has patent protection for key parts of its technology. The Danish-based company is listed on Nasdaq First North Stockholm.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Qlife Holding AB er en medicinsk teknologi virksomhed, der stræber efter at revolutionere markedet for kliniske biomarkører- og virustest. Ved at muliggøre test/diagnostik i hjemmet som et supplement til test i sundhedsvæsenet, lettes adgangen til vigtig helbredsinformation, som kan bidrage til bedre behandling og potentielt forebygge sygdomme. Qlife Holding blev dannet i oktober 2019 og modtog samme år certificeringen ISO 13485:2016, hvilket betyder, at Qlife opfylder alle krav til fremstilling og salg af in vitro diagnostiske analysatorer og reagenser. De første kapsler i virksomhedens produkt, Egoo.Health Platform, blev CE-mærket til professionel brug i begyndelsen af ​​2020. Virksomheden har patentbeskyttelse på centrale dele af sin teknologi.

Qlife Holding

After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent. 

After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&amp;P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent. 
The catch-up by Biotech and Life Science stocks has been long awaited &ndash; and well deserved according to some &ndash; but measured longer term since the beginning of 2023, Biotech and Life Science stocks have still underperformed the general stock market. This is even after the rally in Biotech and Life Science stocks since late October 2023, where Biotech and Life Science stocks are up approximately 50 percent, more than double the increase in MSCI World All Countries. 
The positive resurgence of Biotech and Life Science stocks comes at a time when macroeconomic data continues to be relatively strong, in particular inflation data, which has lowered expectations when central banks will lower interest rates and by how much. Lower interest rates would otherwise often be the sort of contributing trigger that is required for risky assets to move up, but Biotech and Life Science stocks have moved up irrespectively.
If Biotech and Life Science stocks can move up 50 percent in a few months, while sector challenges remain and still missing normal market triggers, it illustrates the extreme negative sentiment we are coming from. Some would suggest it is just mean reversion taking place, which is almost by definition temporary in nature.
The big question is whether the recent increased appetite for risk assets like Biotech and Life Science stocks is indeed, just temporary, or if it is the beginning of a longer period of a more constructive sentiment towards the sector in general. Or if there are circumstances that suggest only some (type of) Biotech and Life Science stocks will continue to move up.
Read full: <a href="https://hcaccapital-stag.agillic.eu/api/webcopy/1620012/%23ZWM/MUvjnTLTpCgkbGMlwALv3w%3D%3D/BioSnack+Marts+2024.html?lgn_uid=LkN4SjoxNzQxODgwNDc2lXOjvCt9NwPbm2L_A6mpsw!!&amp;lang=en&amp;evt=Webcopy&amp;resourcename=BioSnack+Marts+2024&amp;channel=email&amp;lgn_uid=LkN4SjoxNzQxODgyNTU47ZiawS4QV94RLgCbhSIiMg!!&amp;ea=UYcxAD08LtRe-RKQ3B3eCmasKUr4kxmBu6dwr9aRDdlWGM-RmuB63-juHVion_ZD:-OG1akQx8tHOJoJD3VyUig==" target="_blank" rel="noopener">Biosnack newsletter</a>
Disclaimer: HC Andersen Capital receives payment from all companies for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 9:30 AM 14-03-2024.

Stay up to date with our newsletter